dc.contributor.author | Zimmermann, Julie | |
dc.contributor.author | Schmidt, Signe Tandrup | |
dc.contributor.author | Trebbien, Ramona | |
dc.contributor.author | Cox, Rebecca Jane | |
dc.contributor.author | Zhou, Fan | |
dc.contributor.author | Follmann, Frank | |
dc.contributor.author | Pedersen, Gabriel Kristian | |
dc.contributor.author | Christensen, Dennis | |
dc.date.accessioned | 2022-10-05T13:49:30Z | |
dc.date.available | 2022-10-05T13:49:30Z | |
dc.date.created | 2022-05-13T11:05:42Z | |
dc.date.issued | 2022-02-06 | |
dc.identifier.issn | 1661-6596 | |
dc.identifier.uri | https://hdl.handle.net/11250/3024113 | |
dc.description.abstract | The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF®09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 the authors | en_US |
dc.source.articlenumber | 1850 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/ijms23031850 | |
dc.identifier.cristin | 2024293 | |
dc.source.journal | International Journal of Molecular Sciences | en_US |
dc.identifier.citation | International Journal of Molecular Sciences. 2022, 23 (3), 1850. | en_US |
dc.source.volume | 23 | en_US |
dc.source.issue | 3 | en_US |